0001333277-19-000034.txt : 20190208 0001333277-19-000034.hdr.sgml : 20190208 20190208202109 ACCESSION NUMBER: 0001333277-19-000034 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190207 FILED AS OF DATE: 20190208 DATE AS OF CHANGE: 20190208 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GOLDFISCHER CARL CENTRAL INDEX KEY: 0001110780 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36500 FILM NUMBER: 19581563 MAIL ADDRESS: STREET 1: 161 WEST 61ST STREET CITY: NEW YORK STATE: NY ZIP: 10022 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CymaBay Therapeutics, Inc. CENTRAL INDEX KEY: 0001042074 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943103561 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7575 GATEWAY BOULEVARD STREET 2: SUITE 110 CITY: NEWARK STATE: CA ZIP: 94560 BUSINESS PHONE: 510-293-8800 MAIL ADDRESS: STREET 1: 7575 GATEWAY BOULEVARD STREET 2: SUITE 110 CITY: NEWARK STATE: CA ZIP: 94560 FORMER COMPANY: FORMER CONFORMED NAME: METABOLEX, INC. DATE OF NAME CHANGE: 20090721 FORMER COMPANY: FORMER CONFORMED NAME: METABOLEX INC DATE OF NAME CHANGE: 19970710 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2019-02-07 0001042074 CymaBay Therapeutics, Inc. CBAY 0001110780 GOLDFISCHER CARL C/O CYMABAY THERAPEUTICS, INC. 7575 GATEWAY BOULEVARD, SUITE 110 NEWARK CA 94560 1 0 0 0 Common Stock 2019-02-07 4 M 0 2335 5.00 A 2335 D Common Stock 2019-02-07 4 M 0 9340 5.50 A 11675 D Common Stock 2019-02-07 4 S 0 11675 9.0217 D 0 D Stock Option (right to buy) 5.00 2019-02-07 4 M 0 2335 0 D 2023-12-22 Common Stock 2335 0 D Stock Option (right to buy) 5.50 2019-02-07 4 M 0 9340 0 D 2027-06-27 Common Stock 9340 0 D The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.00 to $9.09, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Fully vested. /s/ Sujal Shah, as attorney-in-fact 2019-02-08